SNIPR biome launch Ah A non-commercial patent licensing program that enables field of Crisper Editing in prokaryotes
copenhagen, October 032022: SNIPR Biome ApS (“SNIPR” or the “Company”), a pioneer in CRISPR-based microbial gene therapy, has a portfolio of patents covering the use of the CRISPR/Cas system to edit prokaryotes for academic and non-commercial purposes. announced that it is now available in Research use without written license.
SNIPR has developed a technology platform to precisely target and edit prokaryotes such as bacteria using CRISPR/Cas. The company has an extensive patent portfolio that includes over 20 of his patents granted in the US and Europe. This portfolio broadly covers the fundamental spectrum of safeguarding the use of CRISPR to combat infectious disease pathogens, tailor therapeutic outcomes (e.g. oncology and immunology), and explore novel approaches to the human and animal microbiome. Add gene function. These technologies underpin SNIPR’s broad R&D pipeline addressing the unmet needs of high-risk patient groups. SNIPR lead program (SNIPR001), a CRISPR-armed bacteriophage cocktail targeting antibiotic resistance Escherichia coli A study of infectious diseases in patients with hematologic cancers is currently undergoing Phase I trials in clinics in the United States. This experimental drug is the first orally administered CRISPR-based therapeutic candidate.
SNIPR is committed to enabling and facilitating the development of innovative therapeutics using technology covered by our patent assets. To this end, SNIPR is making its technology available to third parties for research purposes. No written license to SNIPR’s CRISPR tools, methods, or other intellectual property is required for non-commercial academic and non-commercial use. For more information on SNIPR’s patent assets, please visit https://www.sniprbiome.com/snipr-biome-ip.
Dr. Christian GrondahlCo-Founder and CEO of SNIPR Biome, commented: “as part of our commitment Patience with a life-threatening disease, we want to make sure our technologygeeze Maximize your potential. therefore, We believe it matters. When With our own commercial efforts to bring these advances to patients themselves, we enable academic and non-commercial researchers progress of Crisper research and technology Widely available to the global research and discovery community.”
end
almost SNIPR biome
SNIPR Biome is a clinical-stage company developing precision medicines for vulnerable patients with difficult-to-treat conditions. We are pioneering new uses for CRISPR/Cas technology to better treat and prevent human disease through precision killing or genetic modification of bacteria. SNIPR Biome is a leader in this innovative scientific field with ongoing clinical trials, strong IP and a diverse and experienced team. We were the first company to orally administer his CRISPR therapeutic to humans and the first company to obtain a patent for the use of CRISPR to target the microbiome. Additionally, SNIPR has developed a platform to enable gut-directed gene therapy using CRISPR technology. SNIPR is headquartered in Copenhagen, Denmark. For more information, visit www.sniprbiome.com and follow us on LinkedIn and Twitter.
HaContacts
SNIPR biome
Dr. Christian Grøndahl, Co-Founder and CEO
Email: cg@sniprbiome.com
Mobile: +45 20202747
Dr. Eric van der Helm, Head of Scientific Affairs
Email: evdh@sniprbiome.com
Mobile: +45 24653162
www.sniprbiome.com
Follow us on LinkedIn and Twitter: @sniprbiome
Strategic Communication of Concilium
Mary-Jane Elliott, Tracy Chan, Chris Welsh
Phone: +44 (0) 203 709 5700
SNIPR@consilium-comms.com
